Next-Gen Diagnostics and Targeted Therapies Driving the Thymus Cancer Market According to a newly published market research report by 24LifeSciences, global thymus cancer market was valued at USD 149 million in 2026 and is projected to reach USD 213 million by 2034, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. Thymus cancer, clinically referred to as thymoma or thymic carcinoma, is a rare malignancy originating from the epithelial cells of the thymus gland. This small organ, located in the anterior mediastinum, is a crucial part of the immune system responsible for the maturation of T-lymphocytes. Its established role in managing this complex disease underpins its importance in thoracic oncology and rare cancer care. Tumors are classified by the World Health Organization (WHO) into types A, AB, B1, B2, B3, and the more aggressive thymic carcinoma (type C), representing a spectrum of disease that requires highly specialized treatment approaches. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8723/thymus-cancer-market